Review papers with raw data transparency

What the paper does well

• Integrates X‑ray structures (HDLP, HDAC8, HDAC7, HDAC4 homologues) and homology models to justify medicinal chemistry strategies for isoform selectivity and ZBG design Bertrand 2010 structural integration
• Systematic assessment of ZBGs using DFT/ranking rationale (hydroxamate vs alternatives) and mechanistic transition‑state analogues to rationalize potency/selectivity tradeoffs ZBG DFT ranking discussion
• Practical SAR guidance: maps residues in the 11 Å tunnel and surface pockets to cap designs (useful for medicinal chemists)

Limitations, blindspots and what changed since 2010

• Time cutoff: review ends ~2009; does not include genome‑scale chromatin/reader redistribution data showing how HDAC inhibition remodels acetylation landscapes and recruits readers (e.g., BRD4 redistribution) — a mechanistic layer that connects active‑site chemistry to genome‑wide transcription programs Genome-wide BRD4/H4ac after HDACi
• Clinical translation complexities (toxicity, on/off‑target biology, reader dependencies) are mentioned but not integrated with later biomarker/immune‑modulation literature (post‑2010) that informs combination strategies.
• Model vs. in vivo disconnect: many structural-model predictions lacked systematic prospective validation across isoform‑panel biochemical assays and cell‑based readouts at the time.
• Comparative metal identity in vivo (Fe vs Zn) remains debated — Bertrand appropriately highlights metal variability but functional in vivo validation later refined these views (see later mechanistic work).

Concrete reproducible takeaways for researchers

1. Use Bertrand 2010 as an authoritative structural and medicinal‑chemistry map for HDAC active sites (dyads, ZBG constraints, 11 Å tunnel residues, internal cavity) — essential reading before computational design.
2. Don’t rely on ZBG change alone to achieve isoform selectivity: prioritize cap/surface interactions and exploit differences in tunnel residues/internal cavity geometries (Bertrand’s examples: benzamides, nicotinamide scaffolds, internal‑cavity substituents).
3. Integrate genome‑wide chromatin readouts (ChIP‑seq, ATAC, BRD4 mapping) when predicting transcriptional consequences of new HDACi chemotypes — structural binding ≠ transcriptional readout (see Cell Reports 2021) BRD4 redistribution study

Minimal recommended validation workflow (practical)

1. Biochemical panel: purified catalytic domains (HDAC1–3, 4, 6, 8, 10) to measure IC50/Ki across isoforms (include metal replacement tests: Zn/Fe/Co)
2. Structure: co‑crystallography or cryo‑EM with representative compounds (confirm binding mode, ZBG coordination geometry)
3. Cellular: histone/non‑histone acetylation readouts + transcriptomics (RNA‑seq) and BRD4 ChIP‑seq to capture downstream transcriptional redistribution
4. Toxicology/ion channel safety: cardiomyocyte electrophysiology (hiPSC‑CMs) given known HDACi cardiac effects